ARTICLE | Clinical News
BI-505: Ph II discontinued
December 30, 2016 1:42 AM UTC
BioInvent discontinued an open-label, U.S. Phase II trial evaluating IV BI-505 as an add-on therapy in about 90 patients undergoing autologous stem cell transplantation (ASCT) with high-dose melphalan...
BCIQ Company Profiles
BCIQ Target Profiles